The Role of Activism in Shaping Law and Policies that Support Access to Medicines
This article is also available as a PDF here.
Almost 26 years ago, here in Amsterdam, on November 25-26, 1999, Health Action International, Médecins Sans...
Opmerkingen bij de notitie Dwanglicenties van B.J. Bruins, Minister voor Medische Zorg.
Op 15 juni 2018 stuurde Minister Bruins een notitie over dwanglicenties aan de Tweede Kamer. In deze briefing maken wij een aantal voorlopige opmerkingen...
The last mile: A few suggestions for the WHO Pandemic Agreement’s last two weeks...
This technical briefing note is also available as a PDF here.
On 16 April, the Bureau of the Intergovernmental Negotiating Body (INB) to draft and...
Pharmaceutical patents and data exclusivity in an age of AI-driven drug discovery and development
This is an excerpt from a longer report on AI, medicines development and the patent system.
Download the full report here (or by clicking...
Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?
Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Submission to the US International Trade Commission
On 17 June 2022, World Trade Organization (WTO) Members adopted a Ministerial Decision outlining flexibilities in the WTO’s Trade Related Aspects of Intellectual Property...
The European Parliament has now explicitly acknowledged the know-how problem too: time to include...
This technical briefing note is also available as a PDF here.
We have been calling attention to the problem of sharing know-how necessary for the...
How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...
Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...
EU Review of Pharmaceutical Incentives: Recommendations for Change
In 2016, the European Council decided it was time for a review of the incentives that the EU provides to companies that develop new...